Skip to main content

Able Labs Gains From Generic Lortab Approval

The stock adds 8% after the FDA supports the company's new drug application.
  • Author:
  • Publish date:

Able Laboratories


said the Food and Drug Administration approved the company's abbreviated new drug application for a generic version of Lortab, a treatment for moderate to moderately severe pain.

Word that the agency had approved the formulation, consisting of hydrocodone bitartrate and acetaminophen tablets, lifted shares of Able $1.29, or 8%, to $17.55.

Since March 2001, Able, a maker of generic pharmaceuticals, has received 29 abbreviated new drug application approvals. The total market for Able's newly approved drug is estimated at about $230 million, the company said in a press release.